Skip to main content Skip to navigation
Purified Mouse Anti-Human FADD
Product Details
Down Arrow Up Arrow

BD Transduction Laboratories™
Human (QC Testing)
Mouse IgG1
Human FADD aa. 94-208
Western blot (Routinely Tested), Immunofluorescence (Tested During Development), Immunohistochemistry, Immunoprecipitation (Not Recommended)
24 kDa
250 µg/ml
Aqueous buffered solution containing BSA, glycerol, and ≤0.09% sodium azide.

Preparation And Storage

The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. Store undiluted at -20°C.

Product Notices

  1. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
  2. Please refer to for technical protocols.
  3. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
  4. Source of all serum proteins is from USDA inspected abattoirs located in the United States.
610400 Rev. 1
Antibody Details
Down Arrow Up Arrow

During apoptosis, cells exhibit morphological signs of the death process: cell shrinkage, membrane blebbing, and chromatin condensation. The role of the cell surface cytokine receptor, Fas (Apo-1, CD95), in apoptosis has been well characterized. The tumor necrosis factor receptor (TNF-R) can trigger cell death, as well as various other responses. Data suggested that Fas and TNF-R affect a common target in the cell death pathway. This target has been identified as FADD, a novel protein that contains a death domain homologous to the death domains of Fas and TNF-R1. FADD specifically binds to Fas, an association mediated by their homologous death domains. Overexpression of FADD induces apoptosis that is inhibited by CrmA, a poxvirus protein that blocks both Fas- and TNF-induced cell death. Thus, FADD is a central element of the Fas-mediated cell death pathway.

This antibody is routinely tested by western blot analysis. Other applications were tested at BD Biosciences Pharmingen during antibody development only or reported in the literature.

610400 Rev. 1
Format Details
Down Arrow Up Arrow
Tissue culture supernatant is purified by either protein A/G or affinity purification methods. Both methods yield antibody in solution that is free of most other soluble proteins, lipids, etc. This format provides pure antibody that is suitable for a number of downstream applications including: secondary labeling for flow cytometry or microscopy, ELISA, Western blot, etc.
610400 Rev.1
Citations & References
Down Arrow Up Arrow

Development References (5)

  1. Chang DW, Xing Z, Pan Y, et al. c-FLIP(L) is a dual function regulator for caspase-8 activation and CD95-mediated apoptosis. EMBO J. 2002; 21(14):3704-3714. (Biology: Western blot). View Reference
  2. Chinnaiyan AM, O'Rourke K, Tewari M, Dixit VM. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell. 1995; 81(4):505-512. (Biology). View Reference
  3. MacFarlane M, Harper N, Snowden RT, et al. Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia. Oncogene. 2002; 21(44):6809-6818. (Biology: Western blot). View Reference
  4. Micheau O, Thome M, Schneider P, et al. The long form of FLIP is an activator of caspase-8 at the Fas death-inducing signaling complex. J Biol Chem. 2002; 277(47):45162-45171. (Biology: Immunoprecipitation, Western blot). View Reference
  5. Wieder T, Essmann F, Prokop A, et al. Activation of caspase-8 in drug-induced apoptosis of B-lymphoid cells is independent of CD95/Fas receptor-ligand interaction and occurs downstream of caspase-3. Blood. 2001; 97(5):1378-1387. (Biology: Western blot). View Reference
View All (5) View Less
610400 Rev. 1

Please refer to Support Documents for Quality Certificates

Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described

Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims.  Comparisons are not made against non-BD technologies, unless otherwise noted.

For Research Use Only. Not for use in diagnostic or therapeutic procedures.